Nonalcoholic steatohepatitis was renamed, for the first time in 34 years, to metabolic dysfunction associated steatohepatitis (MASH), but a name change is far from being the biggest development in the field, according to experts at Bioplus Interphex (BIX) Korea 2024.
For the time being, Madrigal Pharmaceuticals Inc.’s Rezdiffra (resmetirom) stands alone as the only U.S. FDA approved treatment for treating nonalcoholic steatohepatitis (NASH). But new and positive data from multiple companies show Madrigal may soon have company.
In metabolic dysfunction-associated steatohepatitis (MASH) preclinical models, absence of the lipid droplet-associated protein hydroxysteroid 17β dehydrogenase 13 (17β-HSD13) has been identified as protective against liver fibrosis.
The ongoing European Association for the Study of the Liver 2024 congress in Milan opened yesterday with several presentations on cell plasticity and its role in liver function and regeneration in chronic liver disease situations.
Ochre Bio Ltd. has established a partnership with Boehringer Ingelheim Pharma GmbH & Co. KG focused on the discovery and development of novel first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
In a deal that could exceed $1 billion for Ochre Bio Ltd., the U.K.-based liver disease therapy developer will collaborate with Boehringer Ingelheim GmbH. In the meantime, Hepion Pharmaceuticals Inc. shut down its lead candidate’s phase IIb study while looking for a lifeline.
Building D&D Pharmatech Inc. has been a rollercoaster ride, according to CEO Seulki Lee. The U.S. and Korea-based biotech is on another ascent, having scored U.S. FDA fast track designation for its metabolic dysfunction-associated steatohepatitis (MASH) drug, ahead of its third attempt at a public listing.
Building D&D Pharmatech Inc. has been a rollercoaster ride, according to CEO Seulki Lee. The U.S. and Korea-based biotech is on another ascent, having scored U.S. FDA fast track designation for its metabolic dysfunction-associated steatohepatitis (MASH) drug, ahead of its third attempt at a public listing.
Akero Therapeutics Inc.’s phase IIb data with FGF21 analogue efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) kept interest alive in the face-off between the company and 89bio Inc. with pegozafermin, another FGF21 drug targeting MASH, for which a phase III study is planned.
Max Biopharma Inc. and Metaba LLC are collaborating to study the effects of oxysterol drug candidates that target metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH), idiopathic pulmonary fibrosis, chronic inflammation, and atherosclerosis on metabolic processes.
